Third Harmonic Bio (THRD)

• Market cap: $233M
• 1 day: 0.58%
• 5 days: 48.70%
• 1 month: 48.28%
• 3 months: -10.88%
• 6 months: -60.64%
• Year to date: -53.26%
• 1 year: -54.26%
• 5 years: -73.78%
• 10 years: -73.78%
• Sector: Healthcare
• Industry: Biotechnology

About: Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

Employees: 53

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

95% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 19

92% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 13

13% more funds holding

Funds holding: 85 [Q3] → 96 (+11) [Q4]

7.45% less ownership

Funds ownership: 107.12% [Q3] → 99.67% (-7.45%) [Q4]

23% less capital invested

Capital invested by funds: $597M [Q3] → $462M (-$134M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5 3% downside
• Avg. target: $5 3% downside
• High target: $5 3% downside

2 analyst ratings

• positive: 0 0%
• neutral: 2 100%
• negative: 0 0%

Stifel Alex Thompson 43% 1-year accuracy 3 / 7 met price target	3% downside $5	Hold Downgraded	28 Mar 2025
Morgan Stanley Michael Ulz 20% 1-year accuracy 4 / 20 met price target	3% downside $5	Equal-Weight Downgraded	12 Feb 2025